Payment overview · 2025
General Payments
$137.01
7 reported records · 7 companies
Healthcare provider profile · identity verified
Jeffrey S Howe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELKHART, IN · NPI 1750380424
Verified facts
What the public records show
CMS Open Payments records show Jeffrey S Howe, M.D. received $137.01 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.12 | 16.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.04 | 16.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 14.8% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $19.83 | 14.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 13.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.14 | 13.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.81 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.94 | 5 |
| Education | $39.07 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1102 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 972 | 281 |
| Atorvastatin Calcium | Atorvastatin Calcium | 834 | 249 |
| Losartan Potassium | Losartan Potassium | 546 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 542 | 164 |
| Lisinopril | Lisinopril | 535 | 152 |
| Metformin Hcl Er | Metformin Hcl | 457 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 141 |
| Tamsulosin Hcl | Tamsulosin Hcl | 420 | 127 |
| Omeprazole | Omeprazole | 404 | 107 |
| Simvastatin | Simvastatin | 393 | 110 |
| Alprazolam | Alprazolam | 385 | 82 |
| Furosemide | Furosemide | 327 | 103 |
| Famotidine | Famotidine | 309 | 96 |
| Prednisone | Prednisone | 300 | 205 |
| Meloxicam | Meloxicam | 299 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 82 |
| Gabapentin | Gabapentin | 285 | 74 |
| Glimepiride | Glimepiride | 273 | 83 |
| Sertraline Hcl | Sertraline Hcl | 255 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 84 |
| Azithromycin | Azithromycin | 251 | 203 |
| Trazodone Hcl | Trazodone Hcl | 239 | 58 |
| Montelukast Sodium | Montelukast Sodium | 236 | 67 |
| Clonazepam | Clonazepam | 228 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 52 |
| Tramadol Hcl | Tramadol Hcl | 191 | 67 |
| Irbesartan | Irbesartan | 188 | 59 |
| Potassium Chloride | Potassium Chloride | 185 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 47 |
| Mounjaro | Tirzepatide | 172 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 171 | 45 |
| Lorazepam | Lorazepam | 151 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 31 |
| Metformin Hcl | Metformin Hcl | 139 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 37 |
| Allopurinol | Allopurinol | 137 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 64 |
| Cephalexin | Cephalexin | 134 | 99 |
| Methylprednisolone | Methylprednisolone | 133 | 114 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 42 |
| Bupropion Xl | Bupropion Hcl | 126 | 38 |
| Amoxicillin | Amoxicillin | 124 | 103 |
| Ezetimibe | Ezetimibe | 123 | 38 |
| Carvedilol | Carvedilol | 119 | 41 |
| Cefuroxime | Cefuroxime Axetil | 119 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 37 |
| Synthroid | Levothyroxine Sodium | 119 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 36 |
| Ozempic | Semaglutide | 115 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 31 |
| Pregabalin | Pregabalin | 108 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 33 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 106 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 103 | 23 |
| Atenolol | Atenolol | 101 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 99 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 26 |
| Donepezil Hcl | Donepezil Hcl | 86 | 26 |
| Estradiol | Estradiol | 83 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 60 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 82 | 52 |
| Finasteride | Finasteride | 81 | 19 |
| Alendronate Sodium | Alendronate Sodium | 78 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 24 |
| Celecoxib | Celecoxib | 73 | 28 |
| Warfarin Sodium | Warfarin Sodium | 70 | 15 |
| Jardiance | Empagliflozin | 69 | 20 |
| Trulicity | Dulaglutide | 67 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 65 | 13 |
| Fluconazole | Fluconazole | 63 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 20 |
| Eliquis | Apixaban | 57 | 17 |
| Aripiprazole | Aripiprazole | 56 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 14 |
| Levofloxacin | Levofloxacin | 55 | 42 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 14 |
| Memantine Hcl | Memantine Hcl | 52 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 16 |
| Diazepam | Diazepam | 51 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 50 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 11 |
| Chlorthalidone | Chlorthalidone | 46 | 11 |
| Metronidazole | Metronidazole | 46 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 13 |
| Ondansetron Odt | Ondansetron | 41 | 23 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 40 | suppressed |
| Glipizide | Glipizide | 39 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | 12 |
| Spironolactone | Spironolactone | 39 | 15 |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Famciclovir | Famciclovir | 30 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | 11 |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Zaleplon | Zaleplon | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Testosterone | Testosterone | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.01 · 7 records | Abbott Laboratories | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MATRIDERM, Omnipod, PREVNAR 20, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error